| Literature DB >> 29238132 |
Najat Yahia1, Maya Khoury1, Tania Salloum1, Rita Younes1, Mounzer Saleh1, Esther Myers1.
Abstract
Lebanon is a Middle Eastern country experiencing a surge in the prevalence of type 2 diabetes mellitus among adults. This pilot study evaluated the feasibility and outcomes of implementing the Academy of Nutrition and Dietetics Evidence-Based Nutrition Practice Guidelines (EBNPGs) as part of medical care for patients newly diagnosed with type 2 diabetes mellitus. Seventy-five patients were recruited from 3 Lebanese hospitals, received nutrition care according to EBNPGs, and were followed up for 12 months. Patients achieved significant improvement in clinical outcomes between baseline and 3, 6, and 12 months. Further research is recommended to confirm the benefits of using EBNPGs.Entities:
Keywords: Lebanese patients with type 2 diabetes; clinical outcomes; medical nutrition therapy; therapeutic lifestyle changes; type 2 diabetes nutrition management
Year: 2017 PMID: 29238132 PMCID: PMC5704736 DOI: 10.1097/TIN.0000000000000120
Source DB: PubMed Journal: Top Clin Nutr ISSN: 0883-5691 Impact factor: 0.508
Figure 1.Nutrition progress notes.
Characteristics of the Participating Patients at Enrollment (N = 75)a
| Characteristics | Mean ± SD |
|---|---|
| Age, y | 55 ± 10.7 |
| BMI, kg/m2 | 31.7 ± 4.9 |
| Weight, kg | 83.6 ± 15.0 |
| Caloric intake/d | 1561 ± 428.9 |
Abbreviations: BMI, body mass index; CHO, carbohydrate; SD, standard deviation.
aFemale 39 (52%) and male 36 (48%).
bCHO (48.7%) and fat (32.2%).
Participants' Caloric Intake, Carbohydrate Consumption and Fat Percentage, and Percent Reduction From Baseline by Visit
| Visit | Caloric Intake, kcal Mean ± SD | Carbohydrates, g Mean ± SD | Fat, % Mean ± SD |
|---|---|---|---|
| Visit 1 | 1561.1 ± 428.9 | 190.2 ± 55.9 | 32.2 ± 7.75 |
| Visit 2 | 1471.7 ± 345.4 | 186.8 ± 44.1 | 30.5 ± 5.32 |
| ↓ from baseline, % | 0.02 ± 0.21 | −0.04 ± 0.32 | 0.03 ± 0.14 |
| Visit 3 | 1473.2 ± 283.4 | 186.1 ± 41.8 | 30.7 ± 5.04 |
| ↓ from baseline, % | 0.01 ± 0.18 | −0.04 ± 0.29 | 0.03 ± 0.16 |
| Visit 4 | 1486.9 ± 286.3 | 186.3 ± 44.1 | 30.5 ± 5.58 |
| ↓ from baseline, % | −0.0 ± 0.2 | −0.07 ± 0.34 | 0.04 ± 0.17 |
| Visit 5 | 1558.1 ± 382.7 | 189.3 ± 39.7 | 32.5 ± 5.65 |
| ↓ from baseline, % | −0.06 ± 0.24 | −0.15 ± 0.47 | 0.03 ± 0.12 |
| Significance from zero | 0.12 | 0.032 | 0.075 |
Abbreviation: SD, standard deviation.
Medication Use Among Patients During the Study Period
| Medication | Patients Treated With, % |
|---|---|
| Insulin Humulin 70/30 | 17.1 |
| Insulin Mixtrad 30 | 2.6 |
| Total insulin NPH | 19.7 |
| Insulin Lantus | 1.3 |
| Diamicron | 5.3 |
| Amaryl 4 mg | 3.9 |
| Amaryl 2 mg | 3.9 |
| Glucophage 850 mg | 43.4 |
| Avandia 4 mg | 17.1 |
Comparison of Patients' Pre-/Postresults With 2 Similar Studies and the Academy of Nutrition and Dietetics EBNPGs Target Goal at Baseline and at 12 Monthsa
| Clinical Indicators | Timeframe | Lebanon n = 71 | Comparison to a Study in Turkey | Comparison to a Study in the United States |
|---|---|---|---|---|
| Glycemic control HbA1C, % | ||||
| Baseline and 12-mo findings | Baseline | 9.1 ± 2.3 | 7.7 ± 2.1 | 8.7 ± 2.0 |
| 12 mo | 7.4 ± 1.3 | 6.2 ± 0.9 | ||
| Change from baseline to follow-up at | 3 mo | −1.1 ± 1.8 | −1.4 ± 1.7 | −1.4 ± 2.1 |
| 6 mo | −1.8 ± 2.5 | −1.7 ± 2.0 | ||
| 12 mo | −1.7 ± 2.5 | −1.5 ± 1.9 | ||
| Baseline | 15.5% | 50.8% | ||
| 12 mo | 38.0% | 83.8% | ||
| Patient profile data BMI, kg/m2 | ||||
| Baseline and 12-mofindings | Baseline | 31.7 ± 4.9 | 29.9 ± 5.9 | 34.6 ± 6.2 |
| 12 mo | 30.6 ± 4.9 | 28.9 ± 5.2 | ||
| Change from baseline to follow-up at | 3 mo | −0.7 ± 1.2 | -0.7 ± 1.4 | −0.78 ± 1.68 |
| 6 mo | −0.9 ± 2.2 | −0.94 ± 2.30 | ||
| 12 mo | −1.1 ± 2.7 | −0.9 ± 1.8 | ||
| Baseline | 12.3% | 26.5% | ||
| 12 mo | 13.7% | 29.4% | ||
| Lipid profile | ||||
| LDL, mg/dL | Baseline | 124.7 ± 45.5 | 117.9 ± 40.1 | 119.9 ± 37.0 |
| Baseline and 12-mo findings | 12 mo | 107.3 ± 33.1 | 116.5 ± 38.5 | |
| Change from baseline to follow-up at | 3 mo | −7.3 ± 23.3 | −8.7 ± 32.6 | −2.3 ± 42.6 |
| 6 mo | −14.0 ± 33.7 | −8.9 ± 36.8 | ||
| 12 mo | −17.4 ± 31.4 | −0.9 ± 39.5 | ||
| Baseline | 30.0% | 34.3% | ||
| 12 mo | 50.7% | 27.9% | ||
| HDL, mg/dL | ||||
| Baseline and 12-mo findings | Baseline | 45.3 ± 10.6 | 46.4 ± 11.4 | 43.7 ± 12.4 |
| 12 mo | 47.8 ± 12.9 | 49.1 ± 11.8 | ||
| Change from baseline to follow-up at | 3 mo | ↑1.5 ± 4.7 | ↑2.9 ± 16.9 | ↑0.8 ± 6.6 |
| 6 mo | ↑3.1 ± 7.0 | ↑2.3 ± 9.8 | ||
| 12 mo | ↑2.5 ± 8.6 | ↑2.9 ± 8.7 | ||
| Baseline | 42.0% | 47.8% | ||
| 12 mo | 55.1% | 54.4% | ||
| TG, mg/dL | ||||
| Baseline and 12-mo findings | Baseline | 220.9 ± 223.1 | 197.3 ± 109.6 | 357.1 ± 601.6 |
| 12 mo | 166.4 ± 92.1 | 148.1 ± 77.8 | ||
| Change from baseline to follow-up at | 3 mo | −40.6 ± 218.9 | −46.6 ± 70.4 | −284.4 ± 840.8 |
| 6 mo | −51.4 ± 222.1 | −153.3 ± 660.1 | ||
| 12 mo | −45.4 ± 232.6 | −48.6 ± 75.0 | ||
| Baseline | 36.1% | 34.3% | ||
| 12 mo | 48.6% | 57.4% | ||
| Blood pressure, mm Hg | ||||
| Baseline and 12-mo findings | Baseline | 131.3 ± 20.4 | 134.8 ± 22.3 | 127.0 ± 16.5 |
| 12 mo | 124.9 ± 9.9 | 124.1 ± 11.7 | ||
| Change from baseline to follow-up at | 3 mo | −5.7 ± 15.3 | −9.2 ± 18.7 | −3.8 ± 15.2 |
| 6 mo | −6.9 ± 16.7 | −5.4 ± 16.6 | ||
| 12 mo | −6.4 ± 16.6 | −10.7 ± 20.1 | ||
| Baseline and 12-mo findings | Baseline | 81.3 ± 12.5 | 82.4 ± 9.5 | |
| 12 mo | 78.1 ± 9.5 | 77.4 ± 6.6 | ||
| Change from baseline to follow-up at | 3 mo | −2.5 ± 9.6 | −2.4 ± 17.1 | |
| 6 mo | −3.0 ± 9.0 | |||
| 12 mo | −3.1 ± 9.3 | −5.0 ± 9.9 | ||
| Baseline | 60.0% | 61.8% | ||
| 12 mo | 72.9% | 80.9% | ||
Abbreviations: BMI, body mass index; HbA1C, glycosylated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; TH, triglyceride.
aValues are presented as means ± standard deviations, if not otherwise specified. The minus sign (−) signifies mean decrease from baseline at 3, 6, and 12 months.
The up arrow sign (↑) signifies mean increase from baseline at 3, 6, and 12 months.
bData were missing for 4 patients.
cOverall sample mean.
dMean of individual differences from baseline.
eP < .0001.
fSignifies increase in the difference between test periods.
gGoals from the 2001 Academy of Nutrition and Dietetics EBNPGs for patients with T2DM: HbA1C level of <6% to <7%; BMI >25, then 5% to 10% decrease; LDL-cholesterol level <100 mg/dL; HDL-cholesterol level >45 to >55 mg/dL; systolic blood pressure <130 mm Hg; diastolic blood pressure <80 mm Hg; and blood pressure <130/80 mm Hg.
hP < .01.
iP < .05.
jP < .001.
Figure 2.Dietitians' rating of participants' response to therapeutic lifestyle changes questions at baseline and 12 months using a Likert scale.